Markets:

Overview

News

Currencies

International

Treasuries

Xenon Pharmaceuticals Inc. - Common Shares (NQ:XENE)

35.51 +0.17 (+0.48%)

Delayed Quote Updated: 11:32 AM EDT, Oct 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Xenon Pharmaceuticals Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations And IPOs Take Center Stage ↗

October 10, 2021

Biotech stocks retreated in the week ending Oct. 8, extending losses for the third straight week. Some of the selling in the space was due to money moving out of defensive stocks and into risky bets...

Via Talk Markets

The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations And IPOs Take Center Stage ↗

October 10, 2021

Biotech stocks retreated in the week ending Oct. 8, extending losses for the third straight week. Some of the selling in the space was due to money moving out of defensive...

Via Benzinga

Xenon Pharmaceuticals Raises $300M Via Equity ↗

October 06, 2021

Xenon Pharmaceuticals Inc (NASDAQ: XENE) priced its underwritten public offering of 8.5 million shares and pre-funded warrants to purchase up to 1.7 million shares...

Via Benzinga

Is Xenon Pharmaceuticals a Good Stock to Buy Now? ↗

October 05, 2021

Despite the big run-up yesterday, there could be enough fuel to push this biotech stock even higher.

Via The Motley Fool

The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight ↗

August 08, 2021

Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,...

Via Benzinga

Earnings Scheduled For May 11, 2021 ↗

May 11, 2021

Companies Reporting Before The Bell • Oxford Lane Capital (NASDAQ:OXLC) is estimated to report earnings for its fourth quarter. • ReWalk Robotics (NASDAQ:RWLK) is...

Via Benzinga

The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal ↗

October 06, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) Bicycle Therapeutics plc (...

Via Benzinga

The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout ↗

October 05, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 4) Avadel Pharmaceuticals plc (...

Via Benzinga

44 Biggest Movers From Yesterday ↗

October 05, 2021

Gainers Xenon Pharmaceuticals Inc. (NASDAQ: XENE) shares climbed 101.9% to close at $31.50 on Monday after the company announced its phase 2 study of XEN1101 for the treatment of...

Via Benzinga

Mid-Afternoon Market Update: Dow Drops 375 Points; Elmira Savings Bank Shares Spike Higher ↗

October 04, 2021

Toward the end of trading Monday, the Dow traded down 1.09% to 33,951.17 while the NASDAQ fell 2.28% to 14,234.17. The S&P also fell, dropping 1.49% to 4,292.00. The U.S. has...

Via Benzinga

Topics Stocks

XENE Stock: The Huge FDA News Sending Xenon Pharmaceuticals to the Moon ↗

October 04, 2021

Here's why investors in clinical-stage biotech stock Xenon Pharmaceuticals are cheering today as XENE stock runs wild.

Via InvestorPlace

Mid-Day Market Update: Nasdaq Down 2%; Xenon Pharmaceuticals Shares Jump ↗

October 04, 2021

Midway through trading Monday, the Dow traded down 1.02% to 33,976.93 while the NASDAQ fell 2.14% to 14,255.08. The S&P also fell, dropping 1.23% to 4,303.43. The U.S. has the...

Via Benzinga

Topics Stocks

30 Stocks Moving In Monday's Mid-Day Session ↗

October 04, 2021

Gainers Xenon Pharmaceuticals Inc. (NASDAQ: XENE) shares jumped 71.1% to $26.69 after the company announced its phase 2 study of XEN1101 for the treatment of epilepsy met all...

Via Benzinga

Xenon Pharma Shares Jump After Epilepsy Treatment Phase 2 Data Meets Primary Endpoint ↗

October 04, 2021

Xenon Pharmaceuticals Inc (NASDAQ: XENE) has reported topline results from the Phase 2b X-TOLE trial evaluating XEN1101 as an adjunctive treatment in adult...

Via Benzinga

Mid-Morning Market Update: Markets Mostly Lower; US Factory Orders Surpass Estimates ↗

October 04, 2021

Following the market opening Monday, the Dow traded down 0.01% to 34,326.18 while the NASDAQ fell 1.4% to 14,362.69. The S&P also fell, dropping 0.51% to 4,334.77. The U.S....

Via Benzinga

Topics Stocks

Why Xenon Pharmaceuticals Stock Is Soaring Today ↗

October 04, 2021

Xenon Pharmaceuticals Inc (NASDAQ: XENE) is trading significantly higher Monday after the company announced its phase 2 study of XEN1101 for the treatment of epilepsy met all...

Via Benzinga

Why Xenon Pharmaceuticals Stock Is Screaming Higher Today ↗

October 04, 2021

A positive mid-stage trial is powering this biotech stock higher today.

Via The Motley Fool

Xenon Pharmaceuticals Earnings Perspective: Return On Capital Employed ↗

September 28, 2021

Benzinga Pro data, Xenon Pharmaceuticals (NASDAQ:XENE) reported Q2 sales of $2.22 million. Earnings fell to a loss of $22.50 million, resulting in a 40.1% decrease from last...

Via Benzinga

18 Key Biopharma Catalysts To Keep An Eye On In Q3 ↗

July 10, 2021

Biopharma stocks underperformed in the first half of 2021, and several of these stocks could be in for a rebound in the coming months. Here is a look at some catalysts for the biopharam sector in the...

Via Talk Markets

18 Key Biopharma Catalysts To Keep An Eye On In Q3 ↗

July 10, 2021

Biopharma stocks underperformed in the first half of 2021, and several of these stocks could be in for a rebound in the coming months. Ne...

Via Benzinga

The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering ↗

August 11, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) Alnylam Pharmaceuticals,...

Via Benzinga

Earnings Scheduled For August 11, 2021 ↗

August 11, 2021

Companies Reporting Before The Bell • Wireless Telecom Group (AMEX:WTT) is likely to report earnings for its second quarter. • Gamida Cell (NASDAQ:GMDA) is...

Via Benzinga

Return On Capital Employed Overview: Xenon Pharmaceuticals ↗

June 18, 2021

In Q1, Xenon Pharmaceuticals (NASDAQ:XENE) posted sales of $4.36 million. Earnings were up 24.27%, but Xenon Pharmaceuticals still reported an overall loss of $16.06 million. In...

Via Benzinga

Looking Into Xenon Pharmaceuticals's Return On Capital Employed ↗

June 04, 2021

During Q1, Xenon Pharmaceuticals's (NASDAQ:XENE) reported sales totaled $4.36 million. Despite a 24.27% in earnings, the company posted a loss of $16.06 million. In Q4, Xenon...

Via Benzinga

Xenon Pharmaceuticals's Earnings Outlook ↗

May 10, 2021

Xenon Pharmaceuticals (NASDAQ:XENE) announces its next round of earnings this Tuesday, May 11. Here is Benzinga's everything-that-matters guide for this Tuesday's Q1 earnings...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.